Axecap Investments’s AbbVie ABBV Stock Holding History

Axecap Investments’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$445K	Sell	2,044 -14,276	-87%	-$3.17M	0.31%	49
2025 Q4	$3.73M	Buy	16,320 +14,313	+713%	+$3.26M	2.3%	12
2025 Q3	$465K	Sell	2,007 -25,567	-93%	-$5.21M	0.29%	68
2025 Q2	$5.12M	Buy	27,574 +6,605	+31%	+$1.23M	3.33%	7
2025 Q1	$4.39M	Sell	20,969 -2,870	-12%	-$558K	3.72%	5
2024 Q4	$4.24M	Buy	23,839 +2,005	+9%	+$369K	3.19%	6
2024 Q3	$4.31M	Buy	+21,834	New	+$4.07M	3.27%	3

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Axecap Investments's ABBV Position: Q1 2026 in Review

Axecap Investments reduced its AbbVie (ABBV) stake by 87% in Q1 2026, selling an estimated $3.17M and leaving 2,044 shares worth $445K. The position accounts for 0.31% of the portfolio, ranked #49.

Axecap Investments first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. The position peaked at $5.12M in Q2 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Axecap Investments held 2,044 shares of AbbVie worth $445K as of Q1 2026.
Axecap Investments sold 14,276 AbbVie shares in Q1 2026, an estimated $3.17M.
AbbVie made up 0.31% of Axecap Investments's portfolio in Q1 2026, its #49 holding.
Axecap Investments first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
Axecap Investments's AbbVie position peaked at $5.12M in Q2 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Axecap Investments's 13F filing for Q1 2026, filed 20 Apr 2026.